Ionis Pharmaceuticals, Inc. announced the pricing of $500.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2028 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
